Novel Therapeutics for Fibrotic Disease: Has Their Time Finally Arrived?

Novel TherapeuticsПодробнее

NACFC 2022 | DG02: Wait There Is More — Hidden Effects of Highly Effective Modulator TherapyПодробнее

BenevolentAI & AstraZeneca: finding novel targets for idiopathic pulmonary fibrosisПодробнее

Novel Agents and Combination Therapies in MyelofibrosisПодробнее

Novel Therapy for Cystic Fibrosis Completes Phase 2 TrialПодробнее

FMT & Inflammatory Bowel Disease (IBD): Can Your Gut Heal Itself?Подробнее

NACFC 2022 | W21: Evidence-Based Medicine: Update on Clinical Trials in Cystic FibrosisПодробнее

Novel Mechanistic Insights in Atrial Fibrillation (Sanjiv Narayan, MD) Nov 3, 2016Подробнее

NACFC 2022 | S01: Design of Clinical Trials to Evaluate Nucleotide-Based InterventionsПодробнее

Breaking Barriers in Fibrosis Care: Insights from Industry Leaders at Fibrocor TherapeuticsПодробнее

UofL Dept. of Medicine Grand Rounds: Dr. Jesse RomanПодробнее

Management of Myelofibrosis: JAK Inhibitors and Novel Therapeutics in the Peri-Transplant SettingПодробнее

In the Pipeline: Combating Fibrosis & Inflammation - FibroGenПодробнее

VLC 2023 | New and Novel Clinical Research in the Era of Highly Effective ModulatorsПодробнее

Treatment Options for Pulmonary Fibrosis WebinarПодробнее

Novel therapeutic approachesПодробнее

Novel treatment strategies in myelofibrosisПодробнее